二线激素治疗在复发性前列腺癌管理中的作用。

Role of secondary hormonal therapy in the management of recurrent prostate cancer.

作者信息

Ryan Charles J, Small Eric J

机构信息

Urologic Oncology Program, University of California San Francisco Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California 94143, USA.

出版信息

Urology. 2003 Dec 29;62 Suppl 1:87-94. doi: 10.1016/j.urology.2003.10.002.

DOI:10.1016/j.urology.2003.10.002

PMID:14747046

Abstract

Androgen ablation remains the cornerstone of the systemic management of prostate cancer. After initial androgen deprivation, clinical outcomes vary considerably. For the patient with progressive disease after androgen deprivation, multiple therapeutic options are available and include antiandrogen withdrawal, chemotherapy, and secondary hormonal agents. Multiple secondary hormonal agents have clinical activity and the sequential use of these agents may lead to prolonged periods of clinical response. In addition to the use of oral antiandrogens, active secondary hormonal therapies include adrenolytic agents such as ketoconazole and aminoglutethimide, corticosteroids and estrogenic compounds. This article reviews the clinical trial data for these various agents and discusses their role in the management of patients with advanced prostate cancer.

摘要

雄激素剥夺疗法仍然是前列腺癌全身治疗的基石。初始雄激素剥夺治疗后，临床结果差异很大。对于雄激素剥夺治疗后疾病进展的患者，有多种治疗选择，包括抗雄激素撤药、化疗和二线激素药物。多种二线激素药物具有临床活性，序贯使用这些药物可能会带来较长时间的临床缓解。除了口服抗雄激素药物外，有效的二线激素疗法还包括肾上腺溶解剂，如酮康唑和氨鲁米特、皮质类固醇和雌激素化合物。本文回顾了这些不同药物的临床试验数据，并讨论了它们在晚期前列腺癌患者管理中的作用。